Susquehanna International Group
CADL icon

Susquehanna International Group’s Candel Therapeutics CADL Stock Holding History

Susquehanna International Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
227,939
+114,966
+102% +$868K ﹤0.01% 6109
2026
Q1 		$554K Sell
112,973
-24,435
-18% -$133K ﹤0.01% 9392
2025
Q4 		$776K Sell
137,408
-86,413
-39% -$465K ﹤0.01% 7760
2025
Q3 		$1.14M Sell
223,821
-129,477
-37% -$748K ﹤0.01% 7029
2025
Q2 		$1.79M Buy
353,298
+112,123
+46% +$577K ﹤0.01% 6039
2025
Q1 		$1.36M Sell
241,175
-53,268
-18% -$435K ﹤0.01% 6464
2024
Q4 		$2.56M Buy
294,443
+158,988
+117% +$939K ﹤0.01% 4774
2024
Q3 		$939K Buy
+135,455
New +$841K ﹤0.01% 6933

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group's CADL Position: Q2 2026 in Review

Susquehanna International Group increased its Candel Therapeutics (CADL) stake by 102% in Q2 2026, buying an estimated $868K and bringing the position to 227,939 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #6109.

Susquehanna International Group first reported a position in CADL in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.56M in Q4 2024. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Susquehanna International Group held 227,939 shares of Candel Therapeutics worth $2.35M as of Q2 2026.
  • Susquehanna International Group bought 114,966 Candel Therapeutics shares in Q2 2026, an estimated $868K.
  • Candel Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #6109 holding.
  • Susquehanna International Group first reported a position in Candel Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Susquehanna International Group's Candel Therapeutics position peaked at $2.56M in Q4 2024.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.